ArticleScientific reports2025
Conditional survival analysis and real-time prognosis prediction for prostate cancer patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Risk Factors for Hot Flashes Associated with Androgen Deprivation Therapy in Japanese Patients with Prostate Cancer.JMA journal · 2026Article
- C-X-C chemokine receptor type 4 (CXCR4) antagonism in precision oncology: Clinical applications and future directions.Cancer pathogenesis and therapy · 2026Review
- Personalized Conditional Survival Prediction for Patients with Early-Stage Non-small Cell Lung Cancer.Annals of surgical oncology · 2026Article
- Real-time prognosis prediction with conditional survival analysis for skull base chordoma based on SEER.Translational cancer research · 2025Article
- Construction and validation of a Cox regression-based nomogram model for predicting recurrence risk in early endometrial cancer.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess shifts in long-term survival outcomes for prostate cancer patients, the present study conducted conditional survival (CS) analysis and developed a personalized CS-nomogram to provide dynamic prognostic predictions. Data from 301,441 prostate cancer patients in the Surveillance, epidemiology, and end results (SEER) database were analyzed, with cancer-specific survival (CSS) estimated using the Aalen Johansen estimator. Key predictive factors, including tumor size, lymph node involvement, distant metastasis, and histological grade, were identified via LASSO and multivariable Cox regression analyses to construct the nomogram. Results showed an increase in 12-year CSS from 94.3% at diagnosis to 99.4% for those surviving more than 5 years, with prostate cancer-specific mortality falling below 5% after 5-6 years of survival. The CS-nomogram demonstrated high predictive accuracy, achieving a concordance index (C-index) of 0.869 and area under the curve (AUC) values between 0.847 and 0.904 over a 12-year follow-up period, which provides dynamic, individualized prognostic estimates, supporting the long-term management of prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.